Update on sentinel lymph node biopsy for early-stage vulvar cancer

Brian M. Slomovitz, Robert L. Coleman, Maaike H.M. Oonk, Ate Van Der Zee, Charles Levenback

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Two prospective, multicenter clinical trials have demonstrated the feasibility and reproducibility of sentinel lymph node (SLN) biopsy as part of the standard management of early-stage vulvar carcinoma. On the basis of the results of these trials, many gynecologic oncologists have incorporated SLN biopsy for vulvar cancer into their practice. Studies have further shown that SLN biopsy is associated with better quality of life than full lymphadenectomy, is more cost-effective than full lymphadenectomy, and improved pathologic evaluation. A large observational study is currently evaluating the outcomes of patients with early-stage vulvar cancer according to the results of their SLN biopsy and the approach to their care; this study may confirm that full inguinofemoral lymphadenectomy is no longer necessary in most patients with this disease. Here, we review the published data supporting SLN biopsy as part of the standard of care for women with early-stage vulvar cancer and discuss future considerations for the management of this disease.

Original languageEnglish (US)
Pages (from-to)472-477
Number of pages6
JournalGynecologic oncology
Issue number2
StatePublished - Aug 1 2015


  • Lymphoscintigraphy
  • Sentinel lymph node biopsy
  • Ultrastaging
  • Vulvar cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Update on sentinel lymph node biopsy for early-stage vulvar cancer'. Together they form a unique fingerprint.

Cite this